Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity |
| |
Authors: | Calhoun Royce Jablons David Lau Derick Gandara David R |
| |
Affiliation: | UC Davis Cancer Center, California, USA. |
| |
Abstract: | While 5-year survival rates in patients with stage IB non-small-cell lung cancer (NSCLC) are historically modest (40% to 67%), adjuvant chemotherapy trials including this subgroup have shown little evidence of chemotherapeutic benefit. This article reviews the available data regarding adjuvant chemotherapy following surgically resected stage IB NSCLC, framed within the context of present and future proposed definitions of this diagnosis. The discussion addresses limitations of the current staging system and how this contributes to the mixed results seen with adjuvant treatment. In addition, the authors consider current treatment options for stage IB NSCLC and review planned clinical trials for stage I disease designed to exploit new pharmacogenomic findings. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|